Hope Supports The New James Cancer Hospital And Solove Research Institute

December 21, 2011
Hope Supports The New James Cancer Hospital And Solove Research Institute

COLUMBUS, Ohio – A 31-foot steel beam carrying messages of hope for a cancer-free world from nearly 1,000 James cancer survivors will be installed at 10:30 a.m. Thursday (12/22) at the new Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and critical care tower currently under construction at The Ohio State University Medical Center.

Media are invited to cover the installation of the 1,240-pound beam that was signed by grateful patients and survivors during the 23rd annual Cancer Survivors Day celebration held Sept. 18 at Chemical Abstract Services. Media should park in the Emergency Department parking lot on West 10th Ave., immediately east of Cannon Drive.

The survivor beam will be located on the front side of the new cancer hospital on level five, which is 64 feet above ground. It will be one of more than 10,000 pieces of steel in the building. So far, about 35 percent of the steel pieces have been installed.

Slated to open in 2014, the new James Cancer Hospital will transform the understanding of cancer and cancer treatment, saving lives and dollars. New hope is happening everyday at The James, as our world-class oncologists and researchers unlock the mysteries of why people get sick and, using those discoveries, move from treating cancer to preventing it from ever occurring.

Cancer is the world’s leading killer, claiming more lives than any other disease, act of violence, addiction, war or natural disaster. One in two men and one in three women will be diagnosed with cancer in their lifetimes. The demand for cancer services is expected to strain the existing treatment systems as the incidents of cancer increase nationally 45 percent by 2030. The new James will have expanded capacity to serve cancer patients, growing from today’s 210 beds to 276 beds, meeting the needs of an ever-increasing number of people being diagnosed with cancer.

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers and one of only seven centers funded by the NCI to conduct both phase I and phase II clinical trials. The NCI recently rated Ohio State’s cancer program as “exceptional,” the highest rating given by NCI survey teams. As the cancer program’s 210-bed adult patient-care component, The James is a “Top Hospital” as named by the Leapfrog Group and one of the top 20 cancer hospitals in the nation as ranked by U.S. News & World Report.

# # #

Contact: Gina Bericchia, Medical Center Public Affairs and Media Relations, 614-293-3737, or Gina.Bericchia@osumc.edu

Contact Media Staff

Amanda Harper

Director of Media Relations

614-685-5420 (direct)

614-293-3737 (main)


Media staff are available by calling 614-293-3737 Monday through Friday between 8 a.m. and 5 p.m.


If after hours, please call 614-293-8000 (ask the operator to page the hospital administrative manager).

Latest News

Ohio State, ORIEN Could Play Role in Vice President's Cancer Moonshot Initiative

ORIEN, a network formed by Ohio State and Moffitt Cancer Center, could play an important role in the White House Cancer Moonshot initiative by facilitating the sharing of important data.

Ohio State: An Exceptional Comprehensive Cancer Center Helping Cancer Patients

Director of the OSUCCC Dr. Michael Caligiuri discusses the importance of being an NCI-designated comprehensive cancer center, where research flourishes and the best scientists and physicians want to work.

A Fireside Chat with The James CEO Dr. Michael Caligiuri

Dr. Caligiuri hosts a chat where he talked about the “exceptional” rating The James recently received from the NCI, advances in immunology & how ORIEN could play a role in the cancer “moonshot” program.